The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS -Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study
Open accessPublished version of a preprint
Abstract
Purpose: Onvansertib is a highly specific inhibitor of polo-like kinase 1 (PLK1), with demonstrated safety in solid tumors. We evaluated, preclinically and clinically, the potential of onvansertib in combination with chemotherapy as a therapeutic option for KRAS-mutant colorectal cancer. Patients and Methods: Preclinical activity of onvansertib was assessed (i) in vitro in KRAS wild-type and -mutant isogenic colorectal cancer cells and (ii) in vivo, in combination with irinotecan, in a KRAS-mutant xenograft model. Clinically, a phase Ib trial was conducted to investigate onvansertib at doses 12, 15, and 18 mg/m2 (days 1–5 and 14–19 of a 28-day cycle) in combination with FOLFIRI/bevacizumab (days 1 and 15) in patients with KRAS-mutant metastatic colorectal cancer who had prior oxaliplatin exposure. Safety, efficacy, and changes in circulating tumor DNA (ctDNA) were assessed. Results: In preclinical models, onvansertib displayed superior activity in KRAS-mutant than wild-type isogenic colorectal cancer cells and demonstrated potent antitumor activity in combination with irinotecan in vivo. Eighteen patients enrolled in the phase Ib study. Onvansertib recommended phase II dose was established at 15 mg/m2. Grade 3 and 4 adverse events (AE) represented 15% of all treatment-related AEs, with neutropenia being the most common. Partial responses were observed in 44% of patients, with a median duration of response of 9.5 months. Early ctDNA dynamics were predictive of treatment efficacy. Conclusions: Onvansertib combined with FOLIFRI/bevacizumab exhibited manageable safety and promising efficacy in second-line treatment of patients with KRAS-mutant metastatic colorectal cancer. Further exploration of this combination therapy is ongoing. See related commentary by Stebbing and Bullock, p. 2005
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“KRAS-mutant CRC cells were found to be more sensitive to PLK1 inhibition than their wild-type counterparts [141].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [141]
The cited source says what the claim attributes to it.
In the citing paper
“A clinical study showed promising efficacy of combining the PLK1 inhibitor onvansertib with FOLIFRI/bevacizumab in in KRAS-mutant CRC [141].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [141]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · cited 1×
“In the past two decades, development and approval of mAbs that target angiogenesis (e.g., bevacizumab) and EGFR(cetuximabandpanitumumab)havebeenshowntoenhancethe ef fi cacy of chemotherapy (2, 3).”
Self-citationCunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997 · cited 1×
“Efforts for targeting KRAS in colorectal cancer and other cancers has had very limited progress so far (9), with the exception of the recent success in targeting KRAS-G12C, a relatively rare mutation in colorectal cancer (6, 10).”
KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Arain, M. A., Chen, Y.-J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Farkas, L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0012 · Cited by 1,696 · cited 1×
“Chemotherapy is still the backbone of treatment for the majority of patients in the fi rst-and second-line settings (1).”
Bennouna, J., Sastre, J., Arnold, D., Österlund, P., Greil, R., Van Cutsem, E., von Moos, R., Viéitez, J. M., Bouché, O., Borg, C., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70477-1 · Cited by 1,166 · cited 2×
“This responserateissigni fi cantlygreaterthanthehistorical responserateto FOLFIRI/bevacizumab (12, 13).”
A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
Luo, J., Emanuele, M. J., Li, D., Creighton, C. J., Schlabach, M. R., Westbrook, T. F., Wong, K.-K., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.05.006 · Cited by 1,017 · cited 1×
“A genome-wide short hairpin RNA screen identi fi ed PLK1 inhibition to be synthetic lethal with mutant KRAS in colorectal cancer cells, suggesting that KRAS -mutant colorectal cancer cells are particularly sensitive to PLK1 inhibition (27).”
Hochster, H. S., Hart, L. L., Ramanathan, R. K., Childs, B. H., Hainsworth, J. D., Cohn, A. L., Wong, L., Fehrenbacher, L., Abubakr, Y., Saif, M. W., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.4138 · Cited by 613 · cited 1×
“The most commonly used fi rst-line treatment in patients with mCRC is FOLFOX (folinic acid, fl uorouracil, and oxaliplatin) in combination with bevacizumab, and is associated with a median PFS (mPFS)of8 – 10months(11).”
Douillard, J. Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu141 · Cited by 606 · cited 1×
“However, the bene fi t of EGFR inhibitors is limited to patients with RAS wild-type tumors (3, 4).”
Cited by
Ahn, D. H., Ridinger, M., Cannon, T. L., Mendelsohn, L., Starr, J. S., Hubbard, J. M., Kasi, A., Barzi, A., Samuëlsz, E., Karki, A., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco-24-01266 · Cited by 44
Self-citationStructural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers
Pandey, D., Chauhan, S. C., Kashyap, V. K., & Roy, K. K. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116771 · Cited by 32
Holz, A., Paul, B., Zapf, A., Pantel, K., & Joosse, S. A. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102999 · Cited by 27
Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas
Chiappa, M., Decio, A., Guarrera, L., Mengoli, I., Karki, A., Yemane, D., Ghilardi, C., Scanziani, E., Canesi, S., Barbera, M. C., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06894-1 · Cited by 24
“Onvansertib is an orally available, highly selective PLK1 inhibitor undergoing clinical investigation [21, 22].”
Self-citationExploring Predictive and Prognostic Biomarkers in Colorectal Cancer: A Comprehensive Review
Ashouri, K., Wong, A., Mittal, P., Torres‐Gonzalez, L., Lo, J. H., Soni, S., Algaze, S. D., Khoukaz, T., Zhang, W., Yang, Y., et al. (2024) · Cancers · doi:10.3390/cancers16162796 · Cited by 23
“A Phase 1b/2 trial studied onvansertib, an oral highly selective PLK1 inhibitor, in combination with FOLFIRI and bevacizumab as a second-line treat-ment for KRAS -mutated mCRC and found that the combination was well-tolerated with durable responses [140].”
BackgroundSelf-citation
Metadata
- Authors
- Ahn, D. H., Barzi, A., Ridinger, M., Samuëlsz, E., Subramanian, R. A., Wu, C.-C., Croucher, P. J. P., Smeal, T., Kabbinavar, F. F., & Lenz, H.-J.
- Affiliations
- Mayo Clinic (US)
- City Of Hope National Medical Center (US)
- 3Cardiff Oncology Inc., San Diego, California.
- USC Norris Comprehensive Cancer Center (US)
- Corresponding author
- Lenz, Heinz-Josef
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2024-01-16
- Volume
- 30
- Issue
- 10
- Pages
- 2039-2047
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC11094418
- OpenAlex
- W4390942811
- Cited by
- 49
- References
- 36
- Citations by year
- 2026: 13 · 2025: 24 · 2024: 12
- FWCI
- 8.39
- Type
- journal article
- Language
- en
- Update notices
- correction (2026-03-16)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Clinical Cancer Research (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- n/a (n/a)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- onvansertib, polo-like kinase 1 inhibitor, KRAS-mutant colorectal cancer, metastatic colorectal cancer, second-line therapy, FOLFIRI, bevacizumab, irinotecan, circulating tumor DNA, predictive biomarkers, combination chemotherapy, dose escalation, neutropenia
- MeSH terms
- Bevacizumab, Adult, Aged, Animals, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Leucovorin, Female, Fluorouracil, Humans, Male, Middle Aged, Mutation, Neoplasm Metastasis, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Treatment Outcome, Protein Serine-Threonine Kinases, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS -Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-23-3053
- The paper
- Ahn, D. H., Barzi, A., Ridinger, M., Samuëlsz, E., Subramanian, R. A., Wu, C.-C., Croucher, P. J. P., Smeal, T., Kabbinavar, F. F., & Lenz, H.-J. (2024). Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS -Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-23-3053
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.